

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM363930

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	Notice of Release of Security Interest		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
JPMorgan Chase Bank, N.A.		11/25/2015	national banking association: UNITED STATES
RECEIVING PARTY DATA			
Name:	Solstice Neurosciences, LLC		
Street Address:	4010 Dupont Circle		
Internal Address:	Suites 574, L-07, L-11, 401 and 409		
City:	Louisville		
State/Country:	KENTUCKY		
Postal Code:	40207		
Entity Type:	LIMITED LIABILITY COMPANY: DELAWARE		
PROPERTY NUMBERS Total: 2			
Property Type	Number	Word Mark	
Registration Number:	3812579	SOLSTICE	
Registration Number:	2628983	MYOBLOC	
CORRESPONDENCE DATA			
Fax Number:	9192868199		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	919 286-8000		
Email:	PTO_TMconfirmation@mvalaw.com		
Correspondent Name:	MOORE & VAN ALLEN PLLC		
Address Line 1:	3015 CARRINGTON MILL BOULEVARD		
Address Line 2:	SUITE 400		
Address Line 4:	MORRISVILLE, NORTH CAROLINA 27560		
ATTORNEY DOCKET NUMBER:	036251-23		
NAME OF SUBMITTER:	John E. Slaughter		
SIGNATURE:	/John E. Slaughter/		
DATE SIGNED:	11/30/2015		
Total Attachments: 4			
source=Release Patents and Trademarks Solstice#page1.tif			

OP \$65.00 3812579

source=Release Patents and Trademarks Solstice#page2.tif
source=Release Patents and Trademarks Solstice#page3.tif
source=Release Patents and Trademarks Solstice#page4.tif

NOTICE OF RELEASE OF SECURITY INTEREST

This Notice of Release of Security Interest (the "Release") is effective as of November 25, 2015, by **JPMORGAN CHASE BANK, N.A.** (together with its successors, "Secured Party").

WHEREAS, **SOLSTICE NEUROSCIENCES, LLC**, a Delaware limited liability company (the "Grantor") and Secured Party are parties to a certain Amended and Restated Pledge and Security Agreement dated as of September 20, 2012 (the "Security Agreement"); and

WHEREAS, reference is made to those certain Notices of Security Interest dated as of August 8, 2010 and September 20, 2012 by Grantor in favor of Secured Party (the "Notices"); and

WHEREAS, pursuant to the Security Agreement and Notices, the Grantor granted to the Secured Party a security interest in certain of the Grantor's assets, including, without limitation, the Copyrights, Patents, and Trademarks as defined in the Security Agreement owned by Grantor (collectively, the "Intellectual Property"), including the Intellectual Property listed on Schedule A to the Notice; and


WHEREAS, the Notices were recorded with the trademark division of the United States Patent and Trademark Office on September 26, 2012 at Reel/Frame 4867/0541 and with the patent division of the United States Patent and Trademark Office on August 10, 2010 at Reel/Frame 024812/0430 and on September 26, 2012 at Reel/Frame 029041/0720;

NOW, THEREFORE, intending to be legally bound hereby and in connection with the Security Agreement and Notices, Secured Party hereby releases and remits, without any recourse, representation or warranty, any and all rights, title and interests in and to the Intellectual Property, including, without limitation, the Intellectual Property set forth on Schedule A attached hereto, and hereby authorizes the Grantor or Grantor's authorized representative to record this Release with the United States Patent and Trademark Office as evidence of such release.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, Secured Party duly executes this Release, which is effective as of the day and year first written above.

JPMORGAN CHASE BANK, N.A.,
as Secured Party

By: 
Name: Timothy W. Knealey
Title: Authorized Signer

[Signature Page to Release of Security Interest (Solstice)]

SCHEDULE A

PATENTS

UNITED STATES

TITLE	SERIAL NO.	FILED	REG. NO.	REG. DATE
Stable formulations of botulinum toxin in hydrogels	13440162			
Compositions of activated botulinum holotoxin type b (150 kd)	12462560	8/4/09		
Compositions of activated botulinum toxin type b	12590113	11/3/09		
Compositions of activated botulinum holotoxin type b (150 kd)	12590154	11/3/09		
Stable liquid formulations of botulinum toxin	09393590	9/9/99	7211261	5/1/07
Stable liquid formulations of botulinum toxin	11683628	3/8/07	8173138	5/8/12
Method for treating pain with botulinum toxin type b	09883763	6/18/01	6887476	5/3/05

FOREIGN

TITLE	COUNTRY/ JURISDICTION	REG. NO./APP. NO.
Stable liquid formulations of botulinum toxin	Australia	755556
Stable liquid formulations of botulinum toxin	Canada	2342243
Stable liquid formulations of botulinum toxin	China	ZL998107395
Stable liquid formulations of botulinum toxin	France	1112082
Stable liquid formulations of botulinum toxin	Germany	1112082
Stable liquid formulations of botulinum toxin	Japan	4557426
Stable liquid formulations of botulinum toxin	Japan	2010-43514
Stable liquid formulations of botulinum toxin	Republic of Korea	0699756
Stable liquid formulations of botulinum toxin	Spain	1112082
Stable liquid formulations of botulinum toxin	United Kingdom	1112082

TRADEMARKSUNITED STATES

MARK	SERIAL NO.	FILED	REG. NO.	REG. DATE
SOLSTICE	77595690	10/19/08	3812579	7/6/10
MYOBLOC	76067873	6/9/00	2628983	10/1/02

FOREIGN

MARK	COUNTRY/ JURISDICTION	REG. NO./APP. NO.
MYOBLOC	Brazil	831248556
MYOBLOC	Republic of Korea	4007414680000
NERVIBLOC in Katakana	Japan	4983425
NEUROBLOC	Brazil	831248564
NEUROBLOC	Croatia	Z20072113
NEUROBLOC	Japan	4260255
NEUROBLOC	Liechtenstein	14679
NEUROBLOC	Monaco	27870
NEUROBLOC	Russian Federation	369626
NEUROBLOC	Taiwan	00953986
NEUROBLOC in Katakana	Japan	4498834

0011118.0630781 4830-4548-5611v2